Cipla (CIPLA) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE059A01026
Key metrics
- Market Cap
- ₹1.06 L Cr
- P/E Ratio
- 31.88
- EPS
- 41.23
- Book Value
- 427.35
- P/B Ratio
- 3.12
- ROE
- 11.24%
- ROCE
- 13.79%
- Debt / Equity
- 0.02
- Net Margin
- 14%
- Revenue Growth
- 2.09%
- Profit Growth
- -26.43%
- Dividend Yield
- 0.98%
- 52W High
- ₹1,673.00
- 52W Low
- ₹1,165.70
- Market Cap Band
- large cap
- Face Value
- 2
Ratios computed from the annual results period ending 2026-03-31.
About Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
- Headquarters
- Mumbai, India
- Employees
- 31,369
- Promoter Holding
- 31.13%
Cipla and the Drug Manufacturers - Specialty & Generic industry
Cipla is one of 153 listed companies in the Drug Manufacturers - Specialty & Generic industry. At a P/E of 31.9, it trades in line with the industry median of 30.2.
All Drug Manufacturers - Specialty & Generic stocks →Healthcare sector stocks →
Related companies
- Divi's LaboratoriesDIVISLAB · ₹9,315.00₹2.40 L Cr
- Torrent PharmaceuticalsTORNTPHARM · ₹4,640.00₹1.74 L Cr
- Zydus LifesciencesZYDUSLIFE · ₹1,125.00₹1.12 L Cr
- Laurus LabsLAURUSLABS · ₹2,049.00₹1.10 L Cr
- Dr. Reddy's LaboratoriesDRREDDY · ₹1,234.20₹1.01 L Cr
- Mankind PharmaMANKIND · ₹2,372.00₹96,446 Cr
- Aurobindo PharmaAUROPHARMA · ₹1,684.00₹95,680 Cr
- LupinLUPIN · ₹1,950.00₹89,318 Cr
Cipla: key questions
What does Cipla do?
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally.
What is the share price of Cipla?
Cipla (CIPLA) last traded at ₹1,333.30 on the NSE, up 0.3% on the day. Over the past 52 weeks it has traded between ₹1,165.70 and ₹1,673.00. The current price is 20.3% below its 52-week high.
What is the market cap of Cipla?
Cipla has a market capitalisation of ₹1.06 L Cr, which makes it a large-cap company. It is the 6th largest of 153 listed companies in the Drug Manufacturers - Specialty & Generic industry by market capitalisation.
What is the P/E ratio of Cipla?
Cipla trades at a price-to-earnings (P/E) ratio of 31.9. The median P/E across profitable companies in the Drug Manufacturers - Specialty & Generic industry is 30.2.
What are Cipla's ROE and ROCE?
For the financial year ended March 2026, Cipla reported a return on equity (ROE) of 11.2%, a return on capital employed (ROCE) of 13.8% and a net profit margin of 14.0%.
How fast is Cipla growing?
In the financial year ended March 2026, Cipla's revenue grew 2.1% and net profit fell 26.4% compared with the previous year.
Does Cipla have debt?
Cipla has a debt-to-equity ratio of 0.02, meaning borrowings are about 2% of shareholders' equity.
Does Cipla pay a dividend?
Cipla has a dividend yield of 0.98% at the current share price.
What is the promoter holding in Cipla?
Promoters hold 31.1% of Cipla. Institutional investors hold 44.8%.
Which companies are similar to Cipla?
Listed companies close to Cipla in size within the Drug Manufacturers - Specialty & Generic industry include Divi's Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences, Laurus Labs, Dr. Reddy's Laboratories and Mankind Pharma.
Figures are for information only and are not investment advice.
The full Cipla analysis
Create a free account to open the complete CIPLA deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.